Company 89bio, Inc.

Equities

ETNB

US2825591033

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.26 ^USD	+0.12%		-9.03%	-26.05%

Apr. 17	89bio, Inc. Appoints Martin Babler to Its Board of Directors	CI
Apr. 03	89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	MT

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Companyâs lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.

Number of employees: 70

Managers	Title	Age	Since
Rohan Palekar CEO	Chief Executive Officer	58	18-05-31
Ryan Martins DFI	Director of Finance/CFO	47	19-06-30
Paul Shin COO	Chief Operating Officer	-	20-07-31
Quoc Le-Nguyen CTO	Chief Tech/Sci/R&D Officer	56	19-02-28
Harry Mansbach CTO	Chief Tech/Sci/R&D Officer	59	18-11-30
Jyoti Chauhan LAW	General Counsel	35	-
Amanda Hill HRO	Human Resources Officer	-	20-12-31
Shiva Kumar Natarajan AUD	Comptroller/Controller/Auditor	58	-

Members of the board	Title	Age	Since
Lota Zoth BRD	Director/Board Member	64	20-05-31
Rohan Palekar CEO	Chief Executive Officer	58	18-05-31
Kathy LaPorte BRD	Director/Board Member	62	21-10-31
Michael Hayden FOU	Founder	72	18-03-31
Steven Altschuler CHM	Chairman	70	20-03-22
Derek DiRocco BRD	Director/Board Member	43	18-03-31
Edward Atkinson BRD	Director/Board Member	58	22-02-16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	95,224,724	94,424,344 ( 99.16 %)	0	99.16 %

Name	Equities	%	Valuation
RA Capital Management LP 15.16 %	14,175,398	15.16 %	165 M $
RA Capital Management LP 12.21 %	11,416,948	12.21 %	133 M $
Janus Henderson Investors US LLC 10.78 %	10,081,258	10.78 %	117 M $
Janus Henderson Investors US LLC 9.535 %	8,915,141	9.535 %	104 M $
RTW Investments LP 5.967 %	5,578,931	5.967 %	65 M $
STATE STREET CORPORATION 5.775 %	5,399,358	5.775 %	63 M $
BlackRock Advisors LLC 5.522 %	5,163,186	5.522 %	60 M $
Suvretta Capital Management LLC 5.228 %	4,888,434	5.228 %	57 M $
Pictet Asset Management Holding SA 4.874 %	4,557,680	4.874 %	53 M $
Vanguard Fiduciary Trust Co. 4.607 %	4,307,585	4.607 %	50 M $

89bio, Inc.

142 Sansome Street 2nd floor

94104, San Francisco

http://www.89bio.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.26 USD

Average target price

31.89 USD

Spread / Average Target

+286.06%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
89BIO, INC.	-26.05%	787M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.70%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.26%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs